20-12-15 AMAG Pharmaceuticals : Files Submission in Response to the Food and Drug Administration's Notice of Opportunity for a Hearing and Proposal to Withdraw Approval of Makena AQ
20-12-14 AMAG Pharmaceuticals : Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection) PU
20-11-17 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
20-11-17 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
20-11-16 AMAG Pharmaceuticals : Covis Group Completes Acquisition of AMAG Pharmaceuticals AQ
Manager TitleAgeSince
Director of Finance/CFO - -
President 52 -
Corporate Secretary - -
Director TitleAgeSince
Director/Board Member 52 -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
20-11-15Issuer sale

Chief Executive Officer

1,000,000 2.8983%
20-11-15Issuer sale

Director

118,526 0.3435%
20-11-15Issuer sale

Director

64,764 0.1877%
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%+0.29% - - 477M
+0.93%+2.65%+42.33%+145.77% 1,006B
+1.61%+7.22%+60.81%+47.98% 589B
+3.51%+12.31%+31.15%+78.88% 430B
-1.33%+5.11%+29.26%+21.27% 331B
-0.73%+5.35%+37.44%+23.47% 288B
-1.62%+4.73%+29.04%+39.34% 285B
-2.49%+4.93%-28.67%-42.81% 213B
+0.40%+4.51%+25.85%+55.35% 190B
-1.05%+0.06%+16.91%+59.86% 154B
Average -0.69%+5.96%+27.12%+47.68% 387.31B
Weighted average by Cap. -0.56%+5.38%+34.99%+70.11%
Logo AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
Employees
-
  1. Stock Market
  2. Stocks
  3. AMAG Stock